Advertisement

Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer

Published:September 23, 2022DOI:https://doi.org/10.1016/j.cllc.2022.09.007

      Abstract

      Objectives

      This real-world analysis describes treatment patterns, sequencing and clinical effectiveness, toxicities, and health utility outcomes in advanced-stage, incurable ALK-positive NSCLC patients across five different ALK-TKIs.

      Materials and Methods

      Clinicodemographic, treatment, and toxicity data were collected retrospectively in patients with advanced-stage ALK-positive NSCLC at Princess Margaret Cancer Centre. Patient-reported symptoms, toxicities, and health utilities were collected prospectively.

      Results

      Of 148 ALK-positive NSCLC patients seen July 2009-May 2021, median age was 58.9 years; 84 (57%) were female; 112 (76%) never-smokers; 54 (47%) Asian and 40 (35%) white; 139 (94%) received at least one ALK-TKI: crizotinib (n = 74; 54%) and alectinib (n = 61; 44%) were administered mainly as first-line ALK-TKI, ceritinib, brigatinib and lorlatinib were administered primarily after previous ALK-TKI failure. Median overall survival (OS) was 54.0 months; 31 (21%) patients died within two years of advanced-stage diagnosis. Treatment modifications were observed in 35 (47%) patients with crizotinib, 19 (61%) with ceritinib, 41 (39%) with alectinib, 9 (41%) with brigatinib and 8 (30%) with lorlatinib. Prevalence of dose modifications and self-reported toxicities were higher with early versus later generation ALK-TKIs (P<.05). The presence of early treatment modification was not negatively associated with progression-free survival (PFS) and OS analyses.

      Conclusion

      Serial ALK-TKI sequencing approaches are viable therapeutic options that can extend quality of life and quantity-of-life, though a fifth of patients died within two years. No best single sequencing approach could be determined. Clinically relevant toxicities occurred across all ALK-TKIs. Treatment modifications due to toxicity may not necessarily compromise outcomes, allowing multiple approaches to deal with ALK-TKI toxicities.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Shaw AT
        • Engelman JA.
        ALK in lung cancer: past, present, and future.
        J Clin Oncol. 2013; 31: 1105-1111
        • Remon J
        • Pignataro D
        • Novello S
        • Passiglia F.
        Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
        Cancer Treat Rev. 2021; 95102178
        • Kwak EL
        • Bang YJ
        • Camidge DR
        • Shaw AT
        • Solomon B
        • Maki RG
        • et al.
        Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
        N Engl J Med. 2010; 363: 1693-1703
        • Shaw AT
        • Kim DW
        • Nakagawa K
        • Seto T
        • Crino L
        • Ahn MJ
        • et al.
        Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
        N Engl J Med. 2013; 368: 2385-2394
        • Solomon BJ
        • Mok T
        • Kim DW
        • Wu YL
        • Nakagawa K
        • Mekhail T
        • et al.
        First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
        N Engl J Med. 2014; 371: 2167-2177
        • Soria JC
        • Tan DSW
        • Chiari R
        • Wu YL
        • Paz-Ares L
        • Wolf J
        • et al.
        First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
        Lancet. 2017; 389: 917-929
        • Peters S
        • Camidge DR
        • Shaw AT
        • Gadgeel S
        • Ahn JS
        • Kim DW
        • et al.
        Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
        N Engl J Med. 2017; 377: 829-838
        • Mok T
        • Camidge DR
        • Gadgeel SM
        • Rosell R
        • Dziadziuszko R
        • Kim DW
        • et al.
        Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
        Ann Oncol. 2020; 31: 1056-1064
        • Camidge DR
        • Kim HR
        • Ahn MJ
        • Yang JCH
        • Han JY
        • Hochmair MJ
        • et al.
        Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
        J Clin Oncol. 2020; 38: 3592-3603
        • Shaw AT
        • Bauer TM
        • de Marinis F
        • Felip E
        • Goto Y
        • Liu G
        • et al.
        First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
        N Engl J Med. 2020; 383: 2018-2029
        • Gadgeel S
        • Shaw AT
        • Barlesi F
        • Crino L
        • Yang JC
        • Dingemans AC
        • et al.
        Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
        Br J Cancer. 2018; 118: 38-42
        • Descourt R
        • Perol M
        • Rousseau-Bussac G
        • Planchard D
        • Mennecier B
        • Wislez M
        • et al.
        Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
        Lung Cancer. 2019; 136: 109-114
        • Lin JJ
        • Zhu VW
        • Schoenfeld AJ
        • Yeap BY
        • Saxena A
        • Ferris LA
        • et al.
        Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
        J Thorac Oncol. 2018; 13: 1530-1538
        • Popat S
        • Brustugun OT
        • Cadranel J
        • Felip E
        • Garassino MC
        • Griesinger F
        • et al.
        Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
        Lung Cancer. 2021; 157: 9-16
        • Descourt R
        • Perol M
        • Rousseau-Bussac G
        • Planchard D
        • Mennecier B
        • Wislez M
        • et al.
        Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
        Cancers (Basel). 2022; 14
        • Solomon BJ
        • Besse B
        • Bauer TM
        • Felip E
        • Soo RA
        • Camidge DR
        • et al.
        Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
        Lancet Oncol. 2018; 19: 1654-1667
        • Baldacci S
        • Besse B
        • Avrillon V
        • Mennecier B
        • Mazieres J
        • Dubray-Longeras P
        • et al.
        Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
        Eur J Cancer. 2022; 166: 51-59
        • Pacheco JM
        • Gao D
        • Smith D
        • Purcell T
        • Hancock M
        • Bunn P
        • et al.
        Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.
        J Thorac Oncol. 2019; 14: 691-700
        • Duruisseaux M
        • Besse B
        • Cadranel J
        • Perol M
        • Mennecier B
        • Bigay-Game L
        • et al.
        Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
        Oncotarget. 2017; 8: 21903-21917
        • Britschgi C
        • Addeo A
        • Rechsteiner M
        • Delaloye R
        • Fruh M
        • Metro G
        • et al.
        Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients.
        Front Oncol. 2020; 10: 1299
        • Gibson AJW
        • Box A
        • Dean ML
        • Elegbede AA
        • Hao D
        • Sangha R
        • et al.
        Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors.
        JTO Clin Res Rep. 2021; 2100157
        • Moskovitz M
        • Dudnik E
        • Shamai S
        • Rotenberg Y
        • Popovich-Hadari N
        • Wollner M
        • et al.
        ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
        Oncologist. 2022; 27: e76-e84
        • Tse BC
        • Said BI
        • Fan ZJ
        • Hueniken K
        • Patel D
        • Gill G
        • et al.
        Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment.
        Curr Oncol. 2020; 27: e552-e5e9
        • Bansback N
        • Tsuchiya A
        • Brazier J
        • Anis A.
        Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies.
        PLoS One. 2012; 7: e31115
        • Klimek L
        • Bergmann KC
        • Biedermann T
        • Bousquet J
        • Hellings P
        • Jung K
        • et al.
        Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC).
        Allergo J Int. 2017; 26: 16-24
        • Dueck AC
        • Mendoza TR
        • Mitchell SA
        • Reeve BB
        • Castro KM
        • Rogak LJ
        • et al.
        Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
        JAMA Oncol. 2015; 1: 1051-1059
        • Bagha SM
        • Macedo A
        • Jacks LM
        • Lo C
        • Zimmermann C
        • Rodin G
        • et al.
        The utility of the Edmonton Symptom Assessment System in screening for anxiety and depression.
        Eur J Cancer Care (Engl). 2013; 22: 60-69